Heyu Biological Technology (OTCMKTS:HYBT – Get Free Report) and Semler Scientific (NASDAQ:SMLR – Get Free Report) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.
Analyst Ratings
This is a summary of recent ratings and price targets for Heyu Biological Technology and Semler Scientific, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heyu Biological Technology | 0 | 0 | 0 | 0 | 0.00 |
| Semler Scientific | 0 | 0 | 0 | 1 | 4.00 |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Heyu Biological Technology | $80,000.00 | 145.32 | -$270,000.00 | N/A | N/A |
| Semler Scientific | $58.94 million | 9.71 | $20.58 million | $2.05 | 30.14 |
Semler Scientific has higher revenue and earnings than Heyu Biological Technology.
Volatility and Risk
Heyu Biological Technology has a beta of -17.74, indicating that its stock price is 1,874% less volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.
Insider & Institutional Ownership
49.4% of Semler Scientific shares are owned by institutional investors. 89.2% of Heyu Biological Technology shares are owned by company insiders. Comparatively, 30.2% of Semler Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Heyu Biological Technology and Semler Scientific’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Heyu Biological Technology | -453.55% | -6.43% | -4.43% |
| Semler Scientific | 27.00% | 20.31% | 18.78% |
Summary
Semler Scientific beats Heyu Biological Technology on 9 of the 11 factors compared between the two stocks.
About Heyu Biological Technology
Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.
About Semler Scientific
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company’s products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.
Receive News & Ratings for Heyu Biological Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heyu Biological Technology and related companies with MarketBeat.com's FREE daily email newsletter.
